Transitioning From Luxury Accessory to Medical Device
Eight Sleep is moving away from its reputation as a status symbol for billionaires toward a clinical role in sleep medicine. The company is actively pursuing FDA clearance for technology designed to detect and mitigate sleep apnea. By shifting its focus to this medical application, Eight Sleep aims to move beyond out-of-pocket sales to a model where insurance providers cover the cost of its Pod system.
Matteo Franceschetti, chief executive of Eight Sleep, confirmed that the company's FDA filing process is underway. The firm is currently conducting clinical studies to support these regulatory submissions. While Eight Sleep has funded its own research on sleep apnea in the past, it now needs to meet rigorous standards to prove the Pod can act as a diagnostic or treatment aid rather than just a luxury gadget. The goal is to move the Pod into the same classification as established medical devices.
Clinical Ambitions and Global Research
Regulatory approval for sleep apnea detection would place Eight Sleep in competition with established health-tech companies like Apple and Samsung. These companies have already secured FDA clearance to alert users to potential sleep apnea symptoms. However, Eight Sleep is aiming for a higher bar. The company intends to offer a clinical diagnostic tool that quantifies apnea events per hour.
To build this clinical credibility, the firm is working with international partners. In August 2026, the company began a clinical trial with the Abu Dhabi Department of Health. The study investigates whether the Pod can automatically adjust its position to assist patients with sleep apnea, potentially serving as an alternative to a traditional CPAP machine. Similar research partnerships are becoming common in the region as startups seek to validate their technology through independent health departments.
Examining the Market and Business Strategy
Eight Sleep currently operates in 35 countries and recently entered the Chinese market. Despite its high-end brand image, the company maintains that it wants to shed the luxury label. Eight Sleep raised $50 million from Tether in March 2026, pushing its valuation to $1.5 billion. The company claims it was profitable in 2025 and that cumulative sales for the Pod have topped $500 million.
Direct competition is fierce, and the smart mattress sector has proven unstable. Sleep Number filed for bankruptcy earlier in 2026, highlighting the risks inherent in the hardware-focused sleep industry. Eight Sleep views itself as a health-tech company, aligning more closely with brands like Oura and Whoop than traditional furniture manufacturers. The company faces a significant challenge in proving that its technology treats a medical condition instead of merely tracking sleep data.
Whether insurers will eventually cover the Pod depends on the outcome of current FDA filings. The company continues to refine its technology while attempting to lower costs to broaden its reach. For now, the company remains a favorite among tech executives and athletes, but its long-term future hinges on its ability to satisfy healthcare regulators and shift its perception from a boutique tech product to a standard medical intervention.